human immunodeficiency virus Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Abbott Laboratories determine hiv 1 2
    HIV testing validation procedure. a algorithm used at confirmatory testing:Murex HIV Ab/Ag Combination or Genscreen Ultra HIV Ag-Ab, Serodia HIV1/2 and SD Bioline <t>HIV-1/2</t> 3.0 or Determine HIV-1/2
    Determine Hiv 1 2, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 698 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/determine hiv 1 2/product/Abbott Laboratories
    Average 94 stars, based on 698 article reviews
    Price from $9.99 to $1999.99
    determine hiv 1 2 - by Bioz Stars, 2020-11
    94/100 stars
      Buy from Supplier

    93
    Prospec hiv tat
    Autophagy-related ATG5 and ATG7 are involved in the <t>METH</t> and <t>HIV-Tat-induced</t> autophagy. (A–C) The abundance of ATG5 and ATG7 proteins were detected in HIV-Tat (T100, 100 nM) and/or METH (M, 0.5 mM)-treated cells for 24 h. The β-Actin protein expression levels of ATG5 and ATG7 were analyzed using Western blot, quantified by Image J software, and displayed using the scatter dot plot, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl); # p ≤ 0.05, ## p ≤ 0.01, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (D–G) After the Atg5 and Atg7 genes were silenced, the protein levels of ATG5 and ATG7 were analyzed in cells with or without the HIV-Tat (T100, 100 nM) and METH (M, 0.5 mM) treatment for 24 h. Representative blot images were shown. the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl); ### p ≤ 0.001, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (H) LC3B puncta were detected by fluorescence microscopy to determine the effect of ATG5 and ATG7 on the METH (M, 0.5 mM) and HIV-Tat (T100, 100 nM)-induced autophagy. Representative images were shown. (I) Quantification of LC3B puncta per neuronal cell. A total of five randomly selected neurons in randomly selected fields per treatment were counted. The data were presented as mean ± S.D. ∗∗∗ p ≤ 0.001 compared to the control, ### p ≤ 0.001 compared to the M+T. Representative images were shown.
    Hiv Tat, supplied by Prospec, used in various techniques. Bioz Stars score: 93/100, based on 257 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv tat/product/Prospec
    Average 93 stars, based on 257 article reviews
    Price from $9.99 to $1999.99
    hiv tat - by Bioz Stars, 2020-11
    93/100 stars
      Buy from Supplier

    89
    Gen-Probe human immunodeficiency virus type 1 viral load assay
    Baseline Sociodemographic and Clinical Characteristics of Pregnant Human <t>Immunodeficiency</t> Virus <t>Type</t> 1 (HIV-1)-Infected Women, by Interferon γ Release Assay (IGRA) Response at 32 Weeks Gestation
    Human Immunodeficiency Virus Type 1 Viral Load Assay, supplied by Gen-Probe, used in various techniques. Bioz Stars score: 89/100, based on 154 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human immunodeficiency virus type 1 viral load assay/product/Gen-Probe
    Average 89 stars, based on 154 article reviews
    Price from $9.99 to $1999.99
    human immunodeficiency virus type 1 viral load assay - by Bioz Stars, 2020-11
    89/100 stars
      Buy from Supplier

    91
    Abbott Laboratories realtime hiv 1 assay
    Repeatability of VL below 50 cop/ml in clinical settings. A . Inter-assay variability. The plasma VL of sixty-one samples were tested with the assays from Siemens=Versant <t>HIV-1</t> RNA 1.0 kPCR (Siemens), <t>Abbott=Realtime</t> HIV-1 (Abbott), Roche=Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche). B . Intra-assay repeatability on 40 triplicates tested with Versant HIV-1 RNA 1.0 kPCR (Siemens). C . Intra-assay repeatability on 40 triplicates tested with Realtime HIV-1 (Abbott). D . Intra-assay repeatability on 40 triplicates tested with Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche).
    Realtime Hiv 1 Assay, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 91/100, based on 384 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/realtime hiv 1 assay/product/Abbott Laboratories
    Average 91 stars, based on 384 article reviews
    Price from $9.99 to $1999.99
    realtime hiv 1 assay - by Bioz Stars, 2020-11
    91/100 stars
      Buy from Supplier

    92
    OraSure oraquick advance rapid hiv 1 2 antibody test
    Estimated Impact of Test Performance on Detection of Acute (black) and Established (grey) <t>HIV</t> Infection Cases in San Francisco Targeted Testing Programs. For all blood assays, figures shown represent results shown in Table 3 . For the <t>Oraquick</t> Advance assay, oral fluid results ( Table 2 ) are not shown.
    Oraquick Advance Rapid Hiv 1 2 Antibody Test, supplied by OraSure, used in various techniques. Bioz Stars score: 92/100, based on 272 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oraquick advance rapid hiv 1 2 antibody test/product/OraSure
    Average 92 stars, based on 272 article reviews
    Price from $9.99 to $1999.99
    oraquick advance rapid hiv 1 2 antibody test - by Bioz Stars, 2020-11
    92/100 stars
      Buy from Supplier

    91
    ImmunoGen Inc hiv aids vaccine immunology
    Estimated Impact of Test Performance on Detection of Acute (black) and Established (grey) <t>HIV</t> Infection Cases in San Francisco Targeted Testing Programs. For all blood assays, figures shown represent results shown in Table 3 . For the <t>Oraquick</t> Advance assay, oral fluid results ( Table 2 ) are not shown.
    Hiv Aids Vaccine Immunology, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 91/100, based on 204 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv aids vaccine immunology/product/ImmunoGen Inc
    Average 91 stars, based on 204 article reviews
    Price from $9.99 to $1999.99
    hiv aids vaccine immunology - by Bioz Stars, 2020-11
    91/100 stars
      Buy from Supplier

    92
    Genecopoeia lenti pac hiv expression packaging kit
    Estimated Impact of Test Performance on Detection of Acute (black) and Established (grey) <t>HIV</t> Infection Cases in San Francisco Targeted Testing Programs. For all blood assays, figures shown represent results shown in Table 3 . For the <t>Oraquick</t> Advance assay, oral fluid results ( Table 2 ) are not shown.
    Lenti Pac Hiv Expression Packaging Kit, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 92/100, based on 776 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lenti pac hiv expression packaging kit/product/Genecopoeia
    Average 92 stars, based on 776 article reviews
    Price from $9.99 to $1999.99
    lenti pac hiv expression packaging kit - by Bioz Stars, 2020-11
    92/100 stars
      Buy from Supplier

    92
    Trinity Biotech uni gold hiv
    Flow chart showing the results of <t>HIV</t> testing by HIVST Exacto ® Test HIV and HIV serology national algorithm in the five sites of inclusion, and by the 2012-revised, 2015-consolidated WHO serological algorithm involving three HIV tests at the Reference Provincial Laboratory of <t>Kisangani</t> and finally by molecular biology (measurement of plasma HIV-1 RNA load) at the reference laboratory of Kinshasa. Among the 322 volunteers, five (1.5%) were unable to collect blood, giving a total of 317 participants to be tested in parallel by the HIVST Exacto ® Test HIV, national and 2012-revised, 2015-consolidated WHO serological algorithms and molecular biology. By taking into account the 2012-revised, 2015-consolidated algorithm or the molecular biology for HIV detection as reference diagnosis methods, 262 (82.6%) of the 317 plasmas were non-HIV-infected and 53 (16.7%) were HIV-infected. The HIVST Exacto ® Test HIV provided 262 (82.6%) true HIV-negative plasmas and 55 HIV-positive plasmas, including 53 (16.7%) true HIV-positive and two (0.6%) false-positive plasmas.
    Uni Gold Hiv, supplied by Trinity Biotech, used in various techniques. Bioz Stars score: 92/100, based on 212 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/uni gold hiv/product/Trinity Biotech
    Average 92 stars, based on 212 article reviews
    Price from $9.99 to $1999.99
    uni gold hiv - by Bioz Stars, 2020-11
    92/100 stars
      Buy from Supplier

    94
    Mimetics hiv tcm
    Flow chart showing the results of <t>HIV</t> testing by HIVST Exacto ® Test HIV and HIV serology national algorithm in the five sites of inclusion, and by the 2012-revised, 2015-consolidated WHO serological algorithm involving three HIV tests at the Reference Provincial Laboratory of <t>Kisangani</t> and finally by molecular biology (measurement of plasma HIV-1 RNA load) at the reference laboratory of Kinshasa. Among the 322 volunteers, five (1.5%) were unable to collect blood, giving a total of 317 participants to be tested in parallel by the HIVST Exacto ® Test HIV, national and 2012-revised, 2015-consolidated WHO serological algorithms and molecular biology. By taking into account the 2012-revised, 2015-consolidated algorithm or the molecular biology for HIV detection as reference diagnosis methods, 262 (82.6%) of the 317 plasmas were non-HIV-infected and 53 (16.7%) were HIV-infected. The HIVST Exacto ® Test HIV provided 262 (82.6%) true HIV-negative plasmas and 55 HIV-positive plasmas, including 53 (16.7%) true HIV-positive and two (0.6%) false-positive plasmas.
    Hiv Tcm, supplied by Mimetics, used in various techniques. Bioz Stars score: 94/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv tcm/product/Mimetics
    Average 94 stars, based on 52 article reviews
    Price from $9.99 to $1999.99
    hiv tcm - by Bioz Stars, 2020-11
    94/100 stars
      Buy from Supplier

    92
    Gilead Sciences hiv infection
    Real‐world persistence of E/C/F/TAF versus <t>DTG+ABC/3TC</t> regimens for treatment of <t>HIV</t> in a large Spanish cohort: VACH
    Hiv Infection, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 92/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv infection/product/Gilead Sciences
    Average 92 stars, based on 10 article reviews
    Price from $9.99 to $1999.99
    hiv infection - by Bioz Stars, 2020-11
    92/100 stars
      Buy from Supplier

    92
    Pfizer Inc hiv 1
    Quantitative analysis of the effect of silencing the selected genes on <t>HIV-1</t> and M-PMV particle release. (A) The effect of depleting the individual genes on HIV-1 particle release. HIV1 particle release in the control shRNA or specific shRNA expressing HeLa cells was assessed using a p24 antigen ELISA. Results were expressed as percentage Gag release (supernatant p24/(supernatant + cellular p55/p24)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. (B) Quantitative analysis of the effect of depleting the individual genes on M-PMV particle release. M-PMV particle release in the control shRNA or specific shRNA expressing Cos-1 cells was assessed by immunoblotting with p27 antibody. The supernatant p27 and cellular p27 and Pr78 Gag were quantified on the LiCor Odyssey. Results were expressed as percentage Gag release (supernatant p27/(supernatant + cellular Pr78 Gag /p27)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. A representative of 3 independent experiments is shown in Fig 4B .
    Hiv 1, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 92/100, based on 260 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv 1/product/Pfizer Inc
    Average 92 stars, based on 260 article reviews
    Price from $9.99 to $1999.99
    hiv 1 - by Bioz Stars, 2020-11
    92/100 stars
      Buy from Supplier

    91
    Abbott Laboratories alere determine hiv 1 2
    Endpoint Algorithm for Diagnosis of HIV-1 Infection used at Clinical Sites during the VOICE Study. Participants were monitored monthly for seroconversion with one (Uganda) or two (South Africa and Zimbabwe) third generation HIV rapid diagnostic tests including <t>Alere</t> Determine™ <t>HIV-1/2,</t> OraQuick ADVANCE ® Rapid HIV-1/2 Antibody Test and/or Uni-Gold™ Recombigen ® HIV-1/2. Positive or discordant results were confirmed by GS HIV-1 Western Blot (Western Blot 1) using plasma from a separate draw. HIV-1 RNA PCR (HIV viral load) was performed on plasma following an indeterminate or negative Western blot result to assess acute infection. Participants confirmed as HIV-uninfected resumed study product and continued in VOICE while participants whose Western Blot tested positive returned to the study site to have a second Western blot performed on plasma from a separate draw. A second positive Western blot confirmed HIV infection and the participant was exited from the study. Discordant results underwent investigation and further testing by the Study Laboratory Management Group.
    Alere Determine Hiv 1 2, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 91/100, based on 161 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alere determine hiv 1 2/product/Abbott Laboratories
    Average 91 stars, based on 161 article reviews
    Price from $9.99 to $1999.99
    alere determine hiv 1 2 - by Bioz Stars, 2020-11
    91/100 stars
      Buy from Supplier

    90
    ZeptoMetrix hiv 1 p24 antigen elisa kit
    Treatment of NFκ-B inhibitors reduce <t>HIV-1</t> replication in U1 cells due to BaP exposure. U1 cells were concomitantly treated with BaP (1 µM) and NFκ-B inhibitors, IKK-16 (400 nM) ( A ), and SC-514 (10 µM) ( B ) for 3 days. After the treatment, supernatants were collected to determine the viral load using the <t>p24</t> <t>ELISA</t> assay. HIV-1 replication due to BaP (1 µM) exposure was significantly rescued by NFκ-B inhibitors, IKK-16 (400 nM) and SC-514 (10 µM). *Represents p ≤ 0.05 compared with the control group while ## represents p ≤ 0.005 compared to the BaP-treated groups. Western blots were run using the nuclear fraction proteins obtained from the BaP-exposed cells treated with IKK-16 ( C ) SC-524 ( D ) or siRNA CYP1A1 ( E ) to determine the expression of NFκ-B p65 subunits. The blots indicate that treatment with both the NFκ-B inhibitors and CYP1A1 siRNA reduced the expression of NFκ-B p65 in the nuclear fraction protein of the BaP-treated cells compared to the control. The blots presented are representative of at least three different experiments.
    Hiv 1 P24 Antigen Elisa Kit, supplied by ZeptoMetrix, used in various techniques. Bioz Stars score: 90/100, based on 402 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv 1 p24 antigen elisa kit/product/ZeptoMetrix
    Average 90 stars, based on 402 article reviews
    Price from $9.99 to $1999.99
    hiv 1 p24 antigen elisa kit - by Bioz Stars, 2020-11
    90/100 stars
      Buy from Supplier

    93
    Abbott Laboratories hiv
    3.1. Sensitivity and specificity of <t>RDTs</t> in the detection of <t>HIV</t>
    Hiv, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1471 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv/product/Abbott Laboratories
    Average 93 stars, based on 1471 article reviews
    Price from $9.99 to $1999.99
    hiv - by Bioz Stars, 2020-11
    93/100 stars
      Buy from Supplier

    91
    Meridian Life Science sd bioline hiv 1
    Prevalence of HIV-1 and HIV-2 in pregnant women by calendar year, Simão Mendes National Hospital, Bissau, Guinea-Bissau, 2008–2013. The figure displays the changes in HIV-1 ( a ), HIV-2 ( b ), and <t>HIV-1/2</t> ( c ) prevalence (point estimates and corresponding 95% confidence intervals) among pregnant women presenting for birth by calendar year. HIV-1, HIV-2 and HIV-1/2 all declined significantly from 2009 to 2013 (chi 2 test for trend).
    Sd Bioline Hiv 1, supplied by Meridian Life Science, used in various techniques. Bioz Stars score: 91/100, based on 211 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sd bioline hiv 1/product/Meridian Life Science
    Average 91 stars, based on 211 article reviews
    Price from $9.99 to $1999.99
    sd bioline hiv 1 - by Bioz Stars, 2020-11
    91/100 stars
      Buy from Supplier

    89
    Merck & Co merck hiv 1 vaccine
    Ex vivo HIV-specific CD4+ and CD8+ T cells induced by the <t>Merck</t> trivalent Ad5/HIV vaccine. A) Cytokine and activation marker flow cytometric staining profiles in previously cryopreserved PBMC from one vaccine recipient obtained four weeks after the third immunization (week 30). The Ad5 neutralizing titer for this individual is 893. Cells were gated by forward and side scatter, live vs. dead cells, CD3+ T cells, and then CD4+ and CD8+ T cells. HIV-specific CD4+ (left two columns) and CD8+ (right two columns) T cells were stimulated ex vivo with Gag, Pol and Nef peptide pools that span the sequence encoded by the <t>HIV-1</t> gene insert. The numbers indicate the percent of CD4+ or CD8+ cells expressing cytokine(s) IFN-γ, IL-2 and/or TNF-α. The responses in the negative control were low (
    Merck Hiv 1 Vaccine, supplied by Merck & Co, used in various techniques. Bioz Stars score: 89/100, based on 81 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/merck hiv 1 vaccine/product/Merck & Co
    Average 89 stars, based on 81 article reviews
    Price from $9.99 to $1999.99
    merck hiv 1 vaccine - by Bioz Stars, 2020-11
    89/100 stars
      Buy from Supplier

    93
    Collaborative Drug Discovery Inc hiv 1
    Structural models of (A) BI-1001, (B) CX14442 in complex with <t>HIV-1</t> IN CCD dimer. The averaged structures extracted from the MD trajectories were used. The proteins are shown in cartoon representation with two monomers in yellow and cyan. The BI-1001 and CX14442 are shown in gray stick model. Hydrogen bond interactions are denoted by dotted green or blue lines.
    Hiv 1, supplied by Collaborative Drug Discovery Inc, used in various techniques. Bioz Stars score: 93/100, based on 260 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv 1/product/Collaborative Drug Discovery Inc
    Average 93 stars, based on 260 article reviews
    Price from $9.99 to $1999.99
    hiv 1 - by Bioz Stars, 2020-11
    93/100 stars
      Buy from Supplier

    91
    Celera viroseq hiv 1 genotyping system
    Application of the broadly sensitive <t>genotyping</t> assay in the surveillance of transmitted <t>HIV-1</t> drug resistance in resource-limited countries.
    Viroseq Hiv 1 Genotyping System, supplied by Celera, used in various techniques. Bioz Stars score: 91/100, based on 192 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/viroseq hiv 1 genotyping system/product/Celera
    Average 91 stars, based on 192 article reviews
    Price from $9.99 to $1999.99
    viroseq hiv 1 genotyping system - by Bioz Stars, 2020-11
    91/100 stars
      Buy from Supplier

    92
    Abbott Laboratories hiv antibodies
    Application of the broadly sensitive <t>genotyping</t> assay in the surveillance of transmitted <t>HIV-1</t> drug resistance in resource-limited countries.
    Hiv Antibodies, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 92/100, based on 185 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv antibodies/product/Abbott Laboratories
    Average 92 stars, based on 185 article reviews
    Price from $9.99 to $1999.99
    hiv antibodies - by Bioz Stars, 2020-11
    92/100 stars
      Buy from Supplier

    89
    Trinity Biotech uni gold recombigen hiv test
    Application of the broadly sensitive <t>genotyping</t> assay in the surveillance of transmitted <t>HIV-1</t> drug resistance in resource-limited countries.
    Uni Gold Recombigen Hiv Test, supplied by Trinity Biotech, used in various techniques. Bioz Stars score: 89/100, based on 103 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/uni gold recombigen hiv test/product/Trinity Biotech
    Average 89 stars, based on 103 article reviews
    Price from $9.99 to $1999.99
    uni gold recombigen hiv test - by Bioz Stars, 2020-11
    89/100 stars
      Buy from Supplier

    93
    Hologic Inc aptima hiv 1 quant dx assay
    HIV-specific antibodies Humoral response dynamics were tested up to 1316 days after allo-HSCT. Antibody levels were measured using the standard <t>HIV-1</t> Vitros assay (A), a detuned low-sensitive version of the HIV-1 Vitros assay (B), and the limiting antigen avidity assay (C). White circles represent values under the LOD. Grey shading denotes the period off cART. Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. cART=combined antiretroviral therapy. LOD=limit of detection.
    Aptima Hiv 1 Quant Dx Assay, supplied by Hologic Inc, used in various techniques. Bioz Stars score: 93/100, based on 131 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aptima hiv 1 quant dx assay/product/Hologic Inc
    Average 93 stars, based on 131 article reviews
    Price from $9.99 to $1999.99
    aptima hiv 1 quant dx assay - by Bioz Stars, 2020-11
    93/100 stars
      Buy from Supplier

    92
    Harlan Laboratories hiv 1tg rats
    HIV-specific antibodies Humoral response dynamics were tested up to 1316 days after allo-HSCT. Antibody levels were measured using the standard <t>HIV-1</t> Vitros assay (A), a detuned low-sensitive version of the HIV-1 Vitros assay (B), and the limiting antigen avidity assay (C). White circles represent values under the LOD. Grey shading denotes the period off cART. Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. cART=combined antiretroviral therapy. LOD=limit of detection.
    Hiv 1tg Rats, supplied by Harlan Laboratories, used in various techniques. Bioz Stars score: 92/100, based on 58 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiv 1tg rats/product/Harlan Laboratories
    Average 92 stars, based on 58 article reviews
    Price from $9.99 to $1999.99
    hiv 1tg rats - by Bioz Stars, 2020-11
    92/100 stars
      Buy from Supplier

    Image Search Results


    HIV testing validation procedure. a algorithm used at confirmatory testing:Murex HIV Ab/Ag Combination or Genscreen Ultra HIV Ag-Ab, Serodia HIV1/2 and SD Bioline HIV-1/2 3.0 or Determine HIV-1/2

    Journal: Journal of the International AIDS Society

    Article Title: HIV point of care diagnosis: preventing misdiagnosis experience from a pilot of rapid test algorithm implementation in selected communes in Vietnam

    doi: 10.7448/IAS.20.7.21752

    Figure Lengend Snippet: HIV testing validation procedure. a algorithm used at confirmatory testing:Murex HIV Ab/Ag Combination or Genscreen Ultra HIV Ag-Ab, Serodia HIV1/2 and SD Bioline HIV-1/2 3.0 or Determine HIV-1/2

    Article Snippet: The rapid tests included Determine HIV-1/2 (Alere, Japan) as the screening test and the ACON HIV 1/2 (ACON Laboratories, Sadiego, United States) and DoubleCheckGold HIV 1 & 2 (Orgenics Ltd.,Yavne, Israel) as the second and the third assays (sensitivity and specificity of these three rapid tests are presented in ).

    Techniques:

    Forest plots for rapid test assay Determine HIV-1/2 ® .

    Journal: Frontiers in Immunology

    Article Title: Evaluation of Blood-Based Antibody Rapid Testing for HIV Early Therapy: A Meta-Analysis of the Evidence

    doi: 10.3389/fimmu.2018.01458

    Figure Lengend Snippet: Forest plots for rapid test assay Determine HIV-1/2 ® .

    Article Snippet: The rapid HIV antibody detection assays used in these studies included Capillus HIV-1/HIV-2® (Trinity Biotech, Ireland or Cambridge Diagnostics, Galway, Ireland), Determine HIV-1/2® (Abbott Laboratories, Tokyo, Japan or Inverness Medical Japan Co. Ltd., Japan), Uni-Gold HIV test® (Trinity Biotech, Inc., Wicklow, Ireland), and other independent assays.

    Techniques:

    HIV testing algorithm used for retesting and final confirmation of HIV seroconversion at the Institute of Tropical Medicine, Belgium. EIA 1, Enzygnost Anti-HIV 1/2 Plus (Dade Behring GmbH, Germany); EIA 2, Vironostika HIV Uni-Form II Plus O (Organon Teknika,

    Journal: Clinical and Vaccine Immunology : CVI

    Article Title: Performance of a Rapid and Simple HIV Testing Algorithm in a Multicenter Phase III Microbicide Clinical Trial ▿

    doi: 10.1128/CVI.05069-11

    Figure Lengend Snippet: HIV testing algorithm used for retesting and final confirmation of HIV seroconversion at the Institute of Tropical Medicine, Belgium. EIA 1, Enzygnost Anti-HIV 1/2 Plus (Dade Behring GmbH, Germany); EIA 2, Vironostika HIV Uni-Form II Plus O (Organon Teknika,

    Article Snippet: Specimens were first tested with the Determine HIV-1/2 test (Abbott Laboratories, United Kingdom).

    Techniques: Enzyme-linked Immunosorbent Assay

    Autophagy-related ATG5 and ATG7 are involved in the METH and HIV-Tat-induced autophagy. (A–C) The abundance of ATG5 and ATG7 proteins were detected in HIV-Tat (T100, 100 nM) and/or METH (M, 0.5 mM)-treated cells for 24 h. The β-Actin protein expression levels of ATG5 and ATG7 were analyzed using Western blot, quantified by Image J software, and displayed using the scatter dot plot, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl); # p ≤ 0.05, ## p ≤ 0.01, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (D–G) After the Atg5 and Atg7 genes were silenced, the protein levels of ATG5 and ATG7 were analyzed in cells with or without the HIV-Tat (T100, 100 nM) and METH (M, 0.5 mM) treatment for 24 h. Representative blot images were shown. the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl); ### p ≤ 0.001, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (H) LC3B puncta were detected by fluorescence microscopy to determine the effect of ATG5 and ATG7 on the METH (M, 0.5 mM) and HIV-Tat (T100, 100 nM)-induced autophagy. Representative images were shown. (I) Quantification of LC3B puncta per neuronal cell. A total of five randomly selected neurons in randomly selected fields per treatment were counted. The data were presented as mean ± S.D. ∗∗∗ p ≤ 0.001 compared to the control, ### p ≤ 0.001 compared to the M+T. Representative images were shown.

    Journal: Frontiers in Neuroscience

    Article Title: Autophagy Induction by HIV-Tat and Methamphetamine in Primary Midbrain Neuronal Cells of Tree Shrews via the mTOR Signaling and ATG5/ATG7 Pathway

    doi: 10.3389/fnins.2018.00921

    Figure Lengend Snippet: Autophagy-related ATG5 and ATG7 are involved in the METH and HIV-Tat-induced autophagy. (A–C) The abundance of ATG5 and ATG7 proteins were detected in HIV-Tat (T100, 100 nM) and/or METH (M, 0.5 mM)-treated cells for 24 h. The β-Actin protein expression levels of ATG5 and ATG7 were analyzed using Western blot, quantified by Image J software, and displayed using the scatter dot plot, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl); # p ≤ 0.05, ## p ≤ 0.01, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (D–G) After the Atg5 and Atg7 genes were silenced, the protein levels of ATG5 and ATG7 were analyzed in cells with or without the HIV-Tat (T100, 100 nM) and METH (M, 0.5 mM) treatment for 24 h. Representative blot images were shown. the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl); ### p ≤ 0.001, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (H) LC3B puncta were detected by fluorescence microscopy to determine the effect of ATG5 and ATG7 on the METH (M, 0.5 mM) and HIV-Tat (T100, 100 nM)-induced autophagy. Representative images were shown. (I) Quantification of LC3B puncta per neuronal cell. A total of five randomly selected neurons in randomly selected fields per treatment were counted. The data were presented as mean ± S.D. ∗∗∗ p ≤ 0.001 compared to the control, ### p ≤ 0.001 compared to the M+T. Representative images were shown.

    Article Snippet: To assess the role of HIV-Tat and METH-induced autophagy in primary neuronal cells, two different concentrations of HIV-Tat (50 and 100 nM) were treated individually and in combination with METH (M, 0.5 mM) for 24 h. As shown in Figures , 50 nM HIV-Tat (T50) and 100 nM HIV-Tat (T100) did not strongly elevate the protein expression levels of Beclin-1 and LC3B.

    Techniques: Expressing, Western Blot, Software, Fluorescence, Microscopy

    HIV-Tat synergistically induces autophagy with METH. (A–C) Two different doses of HIV-Tat (T50, 50 nM; T100, 100 nM) were treated in the cells alone or combined with METH (M, 0.5 mM) for 24 h. The β-Actin- protein expression levels of Beclin-1 and LC3B were analyzed using Western blot and quantified by Image J software, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl). # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (D) Ultrastructural analysis of METH and/or HIV-Tat-treated cells by TEM. The red arrows in the micrograph represent the double membrane of the autophagic vesicles. The black boxed area contains representative autophagic vacuoles of METH and HIV-Tat-treated cells at 1,200 magnification. Arrows in the enlarged image indicate double membrane of autophagic vacuoles at 4,000/3,500 magnification. (E) Quantification of autophagic vacuoles per neuronal cell. A total of 10 randomly selected neurons in randomly selected fields per treatment were counted. The data were presented as mean ± S.D. ∗ p ≤ 0.05, and ∗∗∗∗ p ≤ 0.0001 compared to the respective controls (Ctrl). (F) Immunofluorescence staining of mCherry and LC3B in the METH (M, 0.5 mM) and /or HIV-Tat (T100, 100 nM)-treated primary neurons for 24 h. (G) Quantification of LC3B puncta per neuronal cell. A total of 10 randomly selected neurons in randomly selected fields per treatment were counted. The data were presented as mean ± S.D. ∗ or # p ≤ 0.05, and ∗∗∗ or ### p ≤ 0.001 compared to the respective controls (Ctrl-mCherry). Representative images were shown.

    Journal: Frontiers in Neuroscience

    Article Title: Autophagy Induction by HIV-Tat and Methamphetamine in Primary Midbrain Neuronal Cells of Tree Shrews via the mTOR Signaling and ATG5/ATG7 Pathway

    doi: 10.3389/fnins.2018.00921

    Figure Lengend Snippet: HIV-Tat synergistically induces autophagy with METH. (A–C) Two different doses of HIV-Tat (T50, 50 nM; T100, 100 nM) were treated in the cells alone or combined with METH (M, 0.5 mM) for 24 h. The β-Actin- protein expression levels of Beclin-1 and LC3B were analyzed using Western blot and quantified by Image J software, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the respective controls (Ctrl). # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001, compared to the M+T100. The data were presented as mean ± S.D. N = 3 biological replicates per group. (D) Ultrastructural analysis of METH and/or HIV-Tat-treated cells by TEM. The red arrows in the micrograph represent the double membrane of the autophagic vesicles. The black boxed area contains representative autophagic vacuoles of METH and HIV-Tat-treated cells at 1,200 magnification. Arrows in the enlarged image indicate double membrane of autophagic vacuoles at 4,000/3,500 magnification. (E) Quantification of autophagic vacuoles per neuronal cell. A total of 10 randomly selected neurons in randomly selected fields per treatment were counted. The data were presented as mean ± S.D. ∗ p ≤ 0.05, and ∗∗∗∗ p ≤ 0.0001 compared to the respective controls (Ctrl). (F) Immunofluorescence staining of mCherry and LC3B in the METH (M, 0.5 mM) and /or HIV-Tat (T100, 100 nM)-treated primary neurons for 24 h. (G) Quantification of LC3B puncta per neuronal cell. A total of 10 randomly selected neurons in randomly selected fields per treatment were counted. The data were presented as mean ± S.D. ∗ or # p ≤ 0.05, and ∗∗∗ or ### p ≤ 0.001 compared to the respective controls (Ctrl-mCherry). Representative images were shown.

    Article Snippet: To assess the role of HIV-Tat and METH-induced autophagy in primary neuronal cells, two different concentrations of HIV-Tat (50 and 100 nM) were treated individually and in combination with METH (M, 0.5 mM) for 24 h. As shown in Figures , 50 nM HIV-Tat (T50) and 100 nM HIV-Tat (T100) did not strongly elevate the protein expression levels of Beclin-1 and LC3B.

    Techniques: Expressing, Western Blot, Software, Transmission Electron Microscopy, Immunofluorescence, Staining

    Examination of apoptosis in the METH- and/or HIV-Tat-treated neuronal midbrain cells using MTT and TUNEL assays. (A,B) The apoptotic cells were detected by TUNEL assay. The fragmented DNAs were labeled by after the treatment of Rapa, 3-MA and/or Meth + Tat. Scale bars: 100 μm. The percentage of TUNEL-positive cells is presented as mean ± S.E.M. ∗∗∗ p ≤ 0.001compared to the control group. # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001, compared to the combined treatment of HIV-Tat and METH. A total of 10 fields were randomly selected. The data were presented as mean ± S.D. Representative images were shown. (C) Cells viability was detected by MTT assay. The data were presented as mean ± S.D. ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the saline-paired controls (Ctrl); # p ≤ 0.05, ## p ≤ 0.01, compared to the combined treatment of HIV-Tat and METH. Representative images were shown.

    Journal: Frontiers in Neuroscience

    Article Title: Autophagy Induction by HIV-Tat and Methamphetamine in Primary Midbrain Neuronal Cells of Tree Shrews via the mTOR Signaling and ATG5/ATG7 Pathway

    doi: 10.3389/fnins.2018.00921

    Figure Lengend Snippet: Examination of apoptosis in the METH- and/or HIV-Tat-treated neuronal midbrain cells using MTT and TUNEL assays. (A,B) The apoptotic cells were detected by TUNEL assay. The fragmented DNAs were labeled by after the treatment of Rapa, 3-MA and/or Meth + Tat. Scale bars: 100 μm. The percentage of TUNEL-positive cells is presented as mean ± S.E.M. ∗∗∗ p ≤ 0.001compared to the control group. # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001, compared to the combined treatment of HIV-Tat and METH. A total of 10 fields were randomly selected. The data were presented as mean ± S.D. Representative images were shown. (C) Cells viability was detected by MTT assay. The data were presented as mean ± S.D. ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the saline-paired controls (Ctrl); # p ≤ 0.05, ## p ≤ 0.01, compared to the combined treatment of HIV-Tat and METH. Representative images were shown.

    Article Snippet: To assess the role of HIV-Tat and METH-induced autophagy in primary neuronal cells, two different concentrations of HIV-Tat (50 and 100 nM) were treated individually and in combination with METH (M, 0.5 mM) for 24 h. As shown in Figures , 50 nM HIV-Tat (T50) and 100 nM HIV-Tat (T100) did not strongly elevate the protein expression levels of Beclin-1 and LC3B.

    Techniques: MTT Assay, TUNEL Assay, Labeling

    HIV-Tat and METH induce neuronal cells autophagy via the mTOR pathway. (A,B) The abundance of p-mTOR and non-phosphorylated form of mTOR protein were detected in the HIV-Tat (T100, 100 nM) and/or METH (M, 0.5 mM)-treated cells for 24 h. The β-Actin-normalized p-mTOR protein expression level was analyzed using Western blot and quantified by Image J software, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the saline-paired controls (Ctrl); # p ≤ 0.05, compared to the T100+M. The data were presented as mean ± S.D. N = 3 biological replicates per group. (C–G) After the cells were treated with or without 3-MA (50 μm) or Rapa (10 nM) and then treated with METH (M, 0.5 mM) + HIV-Tat (T100, 100 nM) or not for 24 h, the levels of Beclin-1 (C,D) LC3B ( C,E), and p-mTOR (F,G) were detected by Western blot and quantified by Image J software, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the saline-paired controls (Ctrl); # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001, compared to the combined treatment of HIV-Tat and METH. The data were presented as mean ± S.D. N = 3 biological replicates per group.

    Journal: Frontiers in Neuroscience

    Article Title: Autophagy Induction by HIV-Tat and Methamphetamine in Primary Midbrain Neuronal Cells of Tree Shrews via the mTOR Signaling and ATG5/ATG7 Pathway

    doi: 10.3389/fnins.2018.00921

    Figure Lengend Snippet: HIV-Tat and METH induce neuronal cells autophagy via the mTOR pathway. (A,B) The abundance of p-mTOR and non-phosphorylated form of mTOR protein were detected in the HIV-Tat (T100, 100 nM) and/or METH (M, 0.5 mM)-treated cells for 24 h. The β-Actin-normalized p-mTOR protein expression level was analyzed using Western blot and quantified by Image J software, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the saline-paired controls (Ctrl); # p ≤ 0.05, compared to the T100+M. The data were presented as mean ± S.D. N = 3 biological replicates per group. (C–G) After the cells were treated with or without 3-MA (50 μm) or Rapa (10 nM) and then treated with METH (M, 0.5 mM) + HIV-Tat (T100, 100 nM) or not for 24 h, the levels of Beclin-1 (C,D) LC3B ( C,E), and p-mTOR (F,G) were detected by Western blot and quantified by Image J software, with bars showing the means and individual data points of each column. Representative blot images were shown. ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001, compared to the saline-paired controls (Ctrl); # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001, compared to the combined treatment of HIV-Tat and METH. The data were presented as mean ± S.D. N = 3 biological replicates per group.

    Article Snippet: To assess the role of HIV-Tat and METH-induced autophagy in primary neuronal cells, two different concentrations of HIV-Tat (50 and 100 nM) were treated individually and in combination with METH (M, 0.5 mM) for 24 h. As shown in Figures , 50 nM HIV-Tat (T50) and 100 nM HIV-Tat (T100) did not strongly elevate the protein expression levels of Beclin-1 and LC3B.

    Techniques: Expressing, Western Blot, Software

    Graphical summary. METH induces autophagy among primary midbrain neuronal cells and that HIV-Tat synergistically enhances the level of autophagy.

    Journal: Frontiers in Neuroscience

    Article Title: Autophagy Induction by HIV-Tat and Methamphetamine in Primary Midbrain Neuronal Cells of Tree Shrews via the mTOR Signaling and ATG5/ATG7 Pathway

    doi: 10.3389/fnins.2018.00921

    Figure Lengend Snippet: Graphical summary. METH induces autophagy among primary midbrain neuronal cells and that HIV-Tat synergistically enhances the level of autophagy.

    Article Snippet: To assess the role of HIV-Tat and METH-induced autophagy in primary neuronal cells, two different concentrations of HIV-Tat (50 and 100 nM) were treated individually and in combination with METH (M, 0.5 mM) for 24 h. As shown in Figures , 50 nM HIV-Tat (T50) and 100 nM HIV-Tat (T100) did not strongly elevate the protein expression levels of Beclin-1 and LC3B.

    Techniques:

    Baseline Sociodemographic and Clinical Characteristics of Pregnant Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Women, by Interferon γ Release Assay (IGRA) Response at 32 Weeks Gestation

    Journal: The Journal of Infectious Diseases

    Article Title: Latent Tuberculosis Detection by Interferon ? Release Assay during Pregnancy Predicts Active Tuberculosis and Mortality in Human Immunodeficiency Virus Type 1-Infected Women and Their Children

    doi: 10.1086/657411

    Figure Lengend Snippet: Baseline Sociodemographic and Clinical Characteristics of Pregnant Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Women, by Interferon γ Release Assay (IGRA) Response at 32 Weeks Gestation

    Article Snippet: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

    Techniques: Infection, Release Assay

    Rate of Change in CD4 Cell Counts and Log10 Plasma Human Immunodeficiency Virus Type 1 (HIV-1) RNA Levels during Follow-Up in Women with Positive and Negative Tuberculosis Interferon γ Release Assay Responses during Pregnancy

    Journal: The Journal of Infectious Diseases

    Article Title: Latent Tuberculosis Detection by Interferon ? Release Assay during Pregnancy Predicts Active Tuberculosis and Mortality in Human Immunodeficiency Virus Type 1-Infected Women and Their Children

    doi: 10.1086/657411

    Figure Lengend Snippet: Rate of Change in CD4 Cell Counts and Log10 Plasma Human Immunodeficiency Virus Type 1 (HIV-1) RNA Levels during Follow-Up in Women with Positive and Negative Tuberculosis Interferon γ Release Assay Responses during Pregnancy

    Article Snippet: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

    Techniques: Release Assay

    Crude and Adjusted Hazard Ratios (HRs) for Clinical Outcomes in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Women with Positive Tuberculosis Interferon g Release Assay (IGRA) Results, Compared with HIV-1-Infected Women with Negative Tuberculosis

    Journal: The Journal of Infectious Diseases

    Article Title: Latent Tuberculosis Detection by Interferon ? Release Assay during Pregnancy Predicts Active Tuberculosis and Mortality in Human Immunodeficiency Virus Type 1-Infected Women and Their Children

    doi: 10.1086/657411

    Figure Lengend Snippet: Crude and Adjusted Hazard Ratios (HRs) for Clinical Outcomes in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Women with Positive Tuberculosis Interferon g Release Assay (IGRA) Results, Compared with HIV-1-Infected Women with Negative Tuberculosis

    Article Snippet: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

    Techniques: Infection, Release Assay

    Change in CD4 cell count ( left ) and log 10 plasma human immunodeficiency virus type 1 (HIV-1) RNA level ( right ) from enrollment to end of follow-up in women with positive ( dotted line, triangles ) and negative ( solid line, circles ) interferon γ

    Journal: The Journal of Infectious Diseases

    Article Title: Latent Tuberculosis Detection by Interferon ? Release Assay during Pregnancy Predicts Active Tuberculosis and Mortality in Human Immunodeficiency Virus Type 1-Infected Women and Their Children

    doi: 10.1086/657411

    Figure Lengend Snippet: Change in CD4 cell count ( left ) and log 10 plasma human immunodeficiency virus type 1 (HIV-1) RNA level ( right ) from enrollment to end of follow-up in women with positive ( dotted line, triangles ) and negative ( solid line, circles ) interferon γ

    Article Snippet: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

    Techniques: Cell Counting

    Flowchart of human immunodeficiency virus type 1 (HIV-1)-infected women tested for interferon γ release assay (IGRA) responses with use of T-SPOT.TB. TB, tuberculosis.

    Journal: The Journal of Infectious Diseases

    Article Title: Latent Tuberculosis Detection by Interferon ? Release Assay during Pregnancy Predicts Active Tuberculosis and Mortality in Human Immunodeficiency Virus Type 1-Infected Women and Their Children

    doi: 10.1086/657411

    Figure Lengend Snippet: Flowchart of human immunodeficiency virus type 1 (HIV-1)-infected women tested for interferon γ release assay (IGRA) responses with use of T-SPOT.TB. TB, tuberculosis.

    Article Snippet: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

    Techniques: Infection, Release Assay

    Repeatability of VL below 50 cop/ml in clinical settings. A . Inter-assay variability. The plasma VL of sixty-one samples were tested with the assays from Siemens=Versant HIV-1 RNA 1.0 kPCR (Siemens), Abbott=Realtime HIV-1 (Abbott), Roche=Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche). B . Intra-assay repeatability on 40 triplicates tested with Versant HIV-1 RNA 1.0 kPCR (Siemens). C . Intra-assay repeatability on 40 triplicates tested with Realtime HIV-1 (Abbott). D . Intra-assay repeatability on 40 triplicates tested with Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche).

    Journal: BMC Infectious Diseases

    Article Title: HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability

    doi: 10.1186/1471-2334-12-100

    Figure Lengend Snippet: Repeatability of VL below 50 cop/ml in clinical settings. A . Inter-assay variability. The plasma VL of sixty-one samples were tested with the assays from Siemens=Versant HIV-1 RNA 1.0 kPCR (Siemens), Abbott=Realtime HIV-1 (Abbott), Roche=Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche). B . Intra-assay repeatability on 40 triplicates tested with Versant HIV-1 RNA 1.0 kPCR (Siemens). C . Intra-assay repeatability on 40 triplicates tested with Realtime HIV-1 (Abbott). D . Intra-assay repeatability on 40 triplicates tested with Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche).

    Article Snippet: At the target dilution of 12 cop/mL, the Abbott Realtime HIV-1 assay showed the highest rate of undetected samples with 70% of negative results while the others had 20% in comparison.

    Techniques: Inter Assay, Intra Assay

    Low-level VL variability evaluated with a reference sample. Box Plot showing the distribution of 10 replicates of a reference sample at four dilutions (100, 50, 25 and 12 cop/ml or 2, 1.7, 1.4 and 1.1 log cop/ml) tested on each platform. The bottom and the top of the box represent the lower and the upper quartiles respectively. The triangle in the box is the median, and the ends of the whiskers correspond to the minimum and the maximum values. Siemens=Versant HIV-1 RNA 1.0 kPCR (Siemens), Abbott=Realtime HIV-1 (Abbott), Roche=Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche).

    Journal: BMC Infectious Diseases

    Article Title: HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability

    doi: 10.1186/1471-2334-12-100

    Figure Lengend Snippet: Low-level VL variability evaluated with a reference sample. Box Plot showing the distribution of 10 replicates of a reference sample at four dilutions (100, 50, 25 and 12 cop/ml or 2, 1.7, 1.4 and 1.1 log cop/ml) tested on each platform. The bottom and the top of the box represent the lower and the upper quartiles respectively. The triangle in the box is the median, and the ends of the whiskers correspond to the minimum and the maximum values. Siemens=Versant HIV-1 RNA 1.0 kPCR (Siemens), Abbott=Realtime HIV-1 (Abbott), Roche=Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche).

    Article Snippet: At the target dilution of 12 cop/mL, the Abbott Realtime HIV-1 assay showed the highest rate of undetected samples with 70% of negative results while the others had 20% in comparison.

    Techniques:

    Correlation between FTA cards and plasma specimens in HIV-1 RNA quantitation. The red line indicates the best fit of the data to a linear regression. (a) Using the Roche assay. (b) Using the Abbott assay.

    Journal: Access Microbiology

    Article Title: Whatman FTA cards versus plasma specimens for the quantitation of HIV-1 RNA using two real-time PCR assays

    doi: 10.1099/acmi.0.000138

    Figure Lengend Snippet: Correlation between FTA cards and plasma specimens in HIV-1 RNA quantitation. The red line indicates the best fit of the data to a linear regression. (a) Using the Roche assay. (b) Using the Abbott assay.

    Article Snippet: The aim of this study was to evaluate Whatman FTA card (FTA card) specimens for HIV-1 viral load testing compared to plasma specimens using two types of assays: the COBAS AmpliPrep/COBAS TaqMan v2.0 HIV-1 test (Roche) and the Abbott RealTime HIV-1 assay (Abbott).

    Techniques: Quantitation Assay

    Comparison between Whatman FTA cards and plasma specimens in HIV-1 RNA. The boxplot to the left (a) using Roche assay; the boxplot to the right (b) using Abbott assay. The black points in the boxplot indicates the means values. Assay results are in log 10 copies ml −1 .

    Journal: Access Microbiology

    Article Title: Whatman FTA cards versus plasma specimens for the quantitation of HIV-1 RNA using two real-time PCR assays

    doi: 10.1099/acmi.0.000138

    Figure Lengend Snippet: Comparison between Whatman FTA cards and plasma specimens in HIV-1 RNA. The boxplot to the left (a) using Roche assay; the boxplot to the right (b) using Abbott assay. The black points in the boxplot indicates the means values. Assay results are in log 10 copies ml −1 .

    Article Snippet: The aim of this study was to evaluate Whatman FTA card (FTA card) specimens for HIV-1 viral load testing compared to plasma specimens using two types of assays: the COBAS AmpliPrep/COBAS TaqMan v2.0 HIV-1 test (Roche) and the Abbott RealTime HIV-1 assay (Abbott).

    Techniques:

    Bland–Altman analysis between FTA cards and plasma specimens in HIV-1 RNA quantitation. (a) Using the Roche assay. (b) Using the Abbott assay. The black line indicates the bias and the dotted black lines show 95% limits of agreement. Assay results are in log 10 copies ml −1 .

    Journal: Access Microbiology

    Article Title: Whatman FTA cards versus plasma specimens for the quantitation of HIV-1 RNA using two real-time PCR assays

    doi: 10.1099/acmi.0.000138

    Figure Lengend Snippet: Bland–Altman analysis between FTA cards and plasma specimens in HIV-1 RNA quantitation. (a) Using the Roche assay. (b) Using the Abbott assay. The black line indicates the bias and the dotted black lines show 95% limits of agreement. Assay results are in log 10 copies ml −1 .

    Article Snippet: The aim of this study was to evaluate Whatman FTA card (FTA card) specimens for HIV-1 viral load testing compared to plasma specimens using two types of assays: the COBAS AmpliPrep/COBAS TaqMan v2.0 HIV-1 test (Roche) and the Abbott RealTime HIV-1 assay (Abbott).

    Techniques: Quantitation Assay

    Estimated Impact of Test Performance on Detection of Acute (black) and Established (grey) HIV Infection Cases in San Francisco Targeted Testing Programs. For all blood assays, figures shown represent results shown in Table 3 . For the Oraquick Advance assay, oral fluid results ( Table 2 ) are not shown.

    Journal: PLoS ONE

    Article Title: Performance of Rapid Point-of-Care and Laboratory Tests for Acute and Established HIV Infection in San Francisco

    doi: 10.1371/journal.pone.0080629

    Figure Lengend Snippet: Estimated Impact of Test Performance on Detection of Acute (black) and Established (grey) HIV Infection Cases in San Francisco Targeted Testing Programs. For all blood assays, figures shown represent results shown in Table 3 . For the Oraquick Advance assay, oral fluid results ( Table 2 ) are not shown.

    Article Snippet: Between 2005 and 2008, however, several programs serving High Risk MSM, nPEP, Partner Services and Sex Worker populations began providing point-of-care HIV rapid testing [Oraquick Advance Rapid HIV ½ Antibody Test; Orasure Technologies, Bethlehem, PA, USA] for high risk patients, with blood drawn only for completion of RNA testing and/or confirmatory antibody testing in the Public Health Laboratory.

    Techniques: Infection

    Flow chart showing the results of HIV testing by HIVST Exacto ® Test HIV and HIV serology national algorithm in the five sites of inclusion, and by the 2012-revised, 2015-consolidated WHO serological algorithm involving three HIV tests at the Reference Provincial Laboratory of Kisangani and finally by molecular biology (measurement of plasma HIV-1 RNA load) at the reference laboratory of Kinshasa. Among the 322 volunteers, five (1.5%) were unable to collect blood, giving a total of 317 participants to be tested in parallel by the HIVST Exacto ® Test HIV, national and 2012-revised, 2015-consolidated WHO serological algorithms and molecular biology. By taking into account the 2012-revised, 2015-consolidated algorithm or the molecular biology for HIV detection as reference diagnosis methods, 262 (82.6%) of the 317 plasmas were non-HIV-infected and 53 (16.7%) were HIV-infected. The HIVST Exacto ® Test HIV provided 262 (82.6%) true HIV-negative plasmas and 55 HIV-positive plasmas, including 53 (16.7%) true HIV-positive and two (0.6%) false-positive plasmas.

    Journal: PLoS ONE

    Article Title: Evaluation of the practicability and virological performance of finger-stick whole-blood HIV self-testing in French-speaking sub-Saharan Africa

    doi: 10.1371/journal.pone.0189475

    Figure Lengend Snippet: Flow chart showing the results of HIV testing by HIVST Exacto ® Test HIV and HIV serology national algorithm in the five sites of inclusion, and by the 2012-revised, 2015-consolidated WHO serological algorithm involving three HIV tests at the Reference Provincial Laboratory of Kisangani and finally by molecular biology (measurement of plasma HIV-1 RNA load) at the reference laboratory of Kinshasa. Among the 322 volunteers, five (1.5%) were unable to collect blood, giving a total of 317 participants to be tested in parallel by the HIVST Exacto ® Test HIV, national and 2012-revised, 2015-consolidated WHO serological algorithms and molecular biology. By taking into account the 2012-revised, 2015-consolidated algorithm or the molecular biology for HIV detection as reference diagnosis methods, 262 (82.6%) of the 317 plasmas were non-HIV-infected and 53 (16.7%) were HIV-infected. The HIVST Exacto ® Test HIV provided 262 (82.6%) true HIV-negative plasmas and 55 HIV-positive plasmas, including 53 (16.7%) true HIV-positive and two (0.6%) false-positive plasmas.

    Article Snippet: All positive and indeterminate samples by initial WHO II algorithm screening were further re-tested on plasma in the Reference Provincial Laboratory of Kisangani with Alere Determine™ HIV-1/2 (Alere Medical Co. Ltd.) and Uni-Gold™ HIV (Trinity Biotech Manufacturing Ltd.) as the first two HIV tests, followed by a third HIV testing using recomLine HIV-1 and HIV-2® IgG (Biosynex), according to the 2012-revised, 2015-consolidated WHO strategy for HIV testing [ , ].

    Techniques: Flow Cytometry, Infection

    Real‐world persistence of E/C/F/TAF versus DTG+ABC/3TC regimens for treatment of HIV in a large Spanish cohort: VACH

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Real‐world persistence of E/C/F/TAF versus DTG+ABC/3TC regimens for treatment of HIV in a large Spanish cohort: VACH

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques:

    Using Climate‐HIV to describe real‐world clinical outcomes for people living with HIV on dolutegravir‐based regimens

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Using Climate‐HIV to describe real‐world clinical outcomes for people living with HIV on dolutegravir‐based regimens

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques:

    Use of integrase strand transfer inhibitors (INSTIs) in a cohort of HIV‐infected geriatric patients (GEPPO cohort)

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Use of integrase strand transfer inhibitors (INSTIs) in a cohort of HIV‐infected geriatric patients (GEPPO cohort)

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Patient‐reported outcomes in an observational cohort of adult HIV‐1 positive patients after 48 weeks of treatment of darunavir/cobicistat‐based regimens (TMC114FD1HTX4003: ST.O.RE. study)

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Patient‐reported outcomes in an observational cohort of adult HIV‐1 positive patients after 48 weeks of treatment of darunavir/cobicistat‐based regimens (TMC114FD1HTX4003: ST.O.RE. study)

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques:

    Phase IIIb, randomized, open‐label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)‐containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV‐1 infected participants aged ≥60

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Phase IIIb, randomized, open‐label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)‐containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV‐1 infected participants aged ≥60

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Real‐world effects of treatment with emtricitabine/tenofovir alafenamide‐ versus emtricitabine/tenofovir disoproxil fumarate‐based regimens in people living with HIV in a clinical cohort in Germany

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Real‐world effects of treatment with emtricitabine/tenofovir alafenamide‐ versus emtricitabine/tenofovir disoproxil fumarate‐based regimens in people living with HIV in a clinical cohort in Germany

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques:

    Virological response in HIV‐1‐infected patients treated with dolutegravir‐containing ART regimens: a real‐world study

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Virological response in HIV‐1‐infected patients treated with dolutegravir‐containing ART regimens: a real‐world study

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Virological response in HIV‐1‐infected patients treated with dolutegravir‐containing ART regimens: a real‐world study

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Virological response in HIV‐1‐infected patients treated with dolutegravir‐containing ART regimens: a real‐world study

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Viro‐immunological efficacy and tolerability of dolutegravir‐based regimens compared to regimens based on other INI, PI, NNRTI in patients with acute HIV infection: a multicentre cohort study

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Viro‐immunological efficacy and tolerability of dolutegravir‐based regimens compared to regimens based on other INI, PI, NNRTI in patients with acute HIV infection: a multicentre cohort study

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Virological response in HIV‐1‐infected patients treated with dolutegravir‐containing ART regimens: a real‐world study

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Virological response in HIV‐1‐infected patients treated with dolutegravir‐containing ART regimens: a real‐world study

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Pharmacokinetic analysis for darunavir in HIV‐1 infected patients on the cobicistat‐boosted darunavir regimen in an Italian observational, multicentre, prospective study (the TMC114FD1HTX4003 ‐ ST.O.RE. study)

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Pharmacokinetic analysis for darunavir in HIV‐1 infected patients on the cobicistat‐boosted darunavir regimen in an Italian observational, multicentre, prospective study (the TMC114FD1HTX4003 ‐ ST.O.RE. study)

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Dolutegravir + lamivudine dual therapy in patients with suppressed HIV‐RNA: long term virological and immunological results of a multicentre cohort

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Dolutegravir + lamivudine dual therapy in patients with suppressed HIV‐RNA: long term virological and immunological results of a multicentre cohort

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques:

    Real‐world effects of treatment with emtricitabine/tenofovir alafenamide‐ versus emtricitabine/tenofovir disoproxil fumarate‐based regimens in people living with HIV in a clinical cohort in Germany

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: Real‐world effects of treatment with emtricitabine/tenofovir alafenamide‐ versus emtricitabine/tenofovir disoproxil fumarate‐based regimens in people living with HIV in a clinical cohort in Germany

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques:

    High levels of patient satisfaction during rapidly initiated therapy with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) for treatment of HIV‐1 infection through 24 weeks of the DIAMOND study

    Journal: Journal of the International AIDS Society

    Article Title: HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK

    doi: 10.1002/jia2.25187

    Figure Lengend Snippet: High levels of patient satisfaction during rapidly initiated therapy with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) for treatment of HIV‐1 infection through 24 weeks of the DIAMOND study

    Article Snippet: Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): viro‐immunological outcomes of two different integrase inhibitor (INSTI)‐based strategies A Mondi 1 , C Pinnetti1 , P Lorenzini1 , M Plazzi1 , I Abbate2 , G Rozera2 , C Agrati3 , R Libertone1 , S Menichetti1 , I Mastrorosa1 , A Ammassari1 and A Antinori1 1 HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

    Techniques: Infection

    Quantitative analysis of the effect of silencing the selected genes on HIV-1 and M-PMV particle release. (A) The effect of depleting the individual genes on HIV-1 particle release. HIV1 particle release in the control shRNA or specific shRNA expressing HeLa cells was assessed using a p24 antigen ELISA. Results were expressed as percentage Gag release (supernatant p24/(supernatant + cellular p55/p24)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. (B) Quantitative analysis of the effect of depleting the individual genes on M-PMV particle release. M-PMV particle release in the control shRNA or specific shRNA expressing Cos-1 cells was assessed by immunoblotting with p27 antibody. The supernatant p27 and cellular p27 and Pr78 Gag were quantified on the LiCor Odyssey. Results were expressed as percentage Gag release (supernatant p27/(supernatant + cellular Pr78 Gag /p27)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. A representative of 3 independent experiments is shown in Fig 4B .

    Journal: PLoS ONE

    Article Title: An siRNA Screen of Membrane Trafficking Genes Highlights Pathways Common to HIV-1 and M-PMV Virus Assembly and Release

    doi: 10.1371/journal.pone.0106151

    Figure Lengend Snippet: Quantitative analysis of the effect of silencing the selected genes on HIV-1 and M-PMV particle release. (A) The effect of depleting the individual genes on HIV-1 particle release. HIV1 particle release in the control shRNA or specific shRNA expressing HeLa cells was assessed using a p24 antigen ELISA. Results were expressed as percentage Gag release (supernatant p24/(supernatant + cellular p55/p24)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. (B) Quantitative analysis of the effect of depleting the individual genes on M-PMV particle release. M-PMV particle release in the control shRNA or specific shRNA expressing Cos-1 cells was assessed by immunoblotting with p27 antibody. The supernatant p27 and cellular p27 and Pr78 Gag were quantified on the LiCor Odyssey. Results were expressed as percentage Gag release (supernatant p27/(supernatant + cellular Pr78 Gag /p27)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. A representative of 3 independent experiments is shown in Fig 4B .

    Article Snippet: We identified 24 host proteins involved in intracellular trafficking that affected both HIV-1 and M-PMV assembly and release.

    Techniques: shRNA, Expressing, Enzyme-linked Immunosorbent Assay, Standard Deviation

    Bioinformatics analyses of siRNA screen hits. (A) Venn diagram of siRNA hits identified in this work. We identified 41 host proteins in HIV screen and 52 host proteins in M-PMV screen. There were 24 host proteins that were common for both HIV-1 and M-PMV. (B) Protein interaction network of HIV1 screen hits (Stronger associations are represented by thicker lines). A map of the interactions of our HIV screen hits was built by using STRING 9.05 with a required medium confidence score (0.400). Analysis of the network revealed clusters of interrelated factors involved in three distinct pathways (highlighted in grey circle): cellular actin cytoskeletal regulation pathways, clathrin-mediated trafficking factors and regulators of phosphoinositide metabolism. (C) Protein interaction network of the common screen hits for both HIV-1 and M-PMV (Stronger associations are represented by thicker lines). The interactions map of 24 host proteins that were common for both HIV-1 and M-PMV was built by using STRING 9.05 with a required medium confidence score (0.400). Factors involved in clathrin-mediated trafficking, regulation of the actin cytoskeleton, and phosphoinositide metabolism (highlighted in grey circle) were identified to affect both HIV-1 and M-PMV assembly or release.

    Journal: PLoS ONE

    Article Title: An siRNA Screen of Membrane Trafficking Genes Highlights Pathways Common to HIV-1 and M-PMV Virus Assembly and Release

    doi: 10.1371/journal.pone.0106151

    Figure Lengend Snippet: Bioinformatics analyses of siRNA screen hits. (A) Venn diagram of siRNA hits identified in this work. We identified 41 host proteins in HIV screen and 52 host proteins in M-PMV screen. There were 24 host proteins that were common for both HIV-1 and M-PMV. (B) Protein interaction network of HIV1 screen hits (Stronger associations are represented by thicker lines). A map of the interactions of our HIV screen hits was built by using STRING 9.05 with a required medium confidence score (0.400). Analysis of the network revealed clusters of interrelated factors involved in three distinct pathways (highlighted in grey circle): cellular actin cytoskeletal regulation pathways, clathrin-mediated trafficking factors and regulators of phosphoinositide metabolism. (C) Protein interaction network of the common screen hits for both HIV-1 and M-PMV (Stronger associations are represented by thicker lines). The interactions map of 24 host proteins that were common for both HIV-1 and M-PMV was built by using STRING 9.05 with a required medium confidence score (0.400). Factors involved in clathrin-mediated trafficking, regulation of the actin cytoskeleton, and phosphoinositide metabolism (highlighted in grey circle) were identified to affect both HIV-1 and M-PMV assembly or release.

    Article Snippet: We identified 24 host proteins involved in intracellular trafficking that affected both HIV-1 and M-PMV assembly and release.

    Techniques:

    siRNA screen for cellular factors required for HIV-1 and M-PMV assembly and release. (A) Schematic representation of the screen. siRNAs pools were transfected into HeLa or Cos-1 cells on day 1 in a 96-well format. A second transfection with the identical siRNA smartpool together with proviral vector was performed 24 hours after the first transfection. Following an additional 48 hour incubation, particle production in the supernatant was determined by reverse transcription assay. Intracellular GFP expression and cell viability as indicated by PI staining were also measured. (B) siRNA against TSG101 reduces HIV-1 virus output without significantly affecting cell viability and intracellular GFP levels. The scrambled siRNA or TSG siRNA was transfected into HeLa cells with NL4-3-EGFP HIV proviral vector as described above and the effects on HIV particle output, intracellular GFP expression and cell viability were quantified relative to control scrambled siRNA. Error bars indicate the standard deviation of three independent experiments. (C) siRNA against TSG101 reduces M-PMV virus output without significantly affecting cell viability and intracellular GFP levels. The scrambled siRNA or TSG siRNA was transfected into Cos-1 cells with pSARMX-EGFP and pTMO-Env expression vectors as described above and the effects on M-PMV particle output, intracellular GFP expression and cell viability were quantified relative to control scrambled siRNA. Error bars indicate the standard deviation of three independent experiments.

    Journal: PLoS ONE

    Article Title: An siRNA Screen of Membrane Trafficking Genes Highlights Pathways Common to HIV-1 and M-PMV Virus Assembly and Release

    doi: 10.1371/journal.pone.0106151

    Figure Lengend Snippet: siRNA screen for cellular factors required for HIV-1 and M-PMV assembly and release. (A) Schematic representation of the screen. siRNAs pools were transfected into HeLa or Cos-1 cells on day 1 in a 96-well format. A second transfection with the identical siRNA smartpool together with proviral vector was performed 24 hours after the first transfection. Following an additional 48 hour incubation, particle production in the supernatant was determined by reverse transcription assay. Intracellular GFP expression and cell viability as indicated by PI staining were also measured. (B) siRNA against TSG101 reduces HIV-1 virus output without significantly affecting cell viability and intracellular GFP levels. The scrambled siRNA or TSG siRNA was transfected into HeLa cells with NL4-3-EGFP HIV proviral vector as described above and the effects on HIV particle output, intracellular GFP expression and cell viability were quantified relative to control scrambled siRNA. Error bars indicate the standard deviation of three independent experiments. (C) siRNA against TSG101 reduces M-PMV virus output without significantly affecting cell viability and intracellular GFP levels. The scrambled siRNA or TSG siRNA was transfected into Cos-1 cells with pSARMX-EGFP and pTMO-Env expression vectors as described above and the effects on M-PMV particle output, intracellular GFP expression and cell viability were quantified relative to control scrambled siRNA. Error bars indicate the standard deviation of three independent experiments.

    Article Snippet: We identified 24 host proteins involved in intracellular trafficking that affected both HIV-1 and M-PMV assembly and release.

    Techniques: Transfection, Plasmid Preparation, Incubation, Expressing, Staining, Standard Deviation

    Effect of silencing of TSG101, ALIX1, AP1M1, BECN1 and SARA1 on HIV-1 and M-PMV particle output. (A) Quantitative western blots showing knockdown efficiency of the individual genes in Jurkat cells and Cos-1 cells. Jurkat cells and Cos-1 cells stably expressing control shRNA or specific shRNAs against individual genes were generated, and the cellular levels of the individual proteins examined by immunoblotting. The ratio of the individual protein levels as quantified on the LiCor Odyssey compared to control cell is shown below each blot. (B) The effect of depleting the individual genes on M-PMV particle output. Cos-1 cells stably expressing control shRNA or the indicated shRNAs were transfected with pSARMX M-PMV proviral vector. At 48 hours after transfection, the virions in the supernatant and cell lysates were harvested and subjected to immunoblotting with p27 antibody. The ratio of supernatant p27 and the ratio of the total amount of cellular p27 and Pr78 Gag as quantified on the LiCor Odyssey compared to control cells are shown below each blot. (C) The effect of depleting the individual genes on HIV-1 particle release in Jurkat cells. Control shRNA or specific shRNA expressing Jurkat cells were infected with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-NL4-3 virus (at 1 TCID 50 ) overnight at 37°C, washed and then seeded in 12-well plates. HIV-1 particle release was assessed using a p24 antigen ELISA 2 days post-infection. Results were expressed as percentage Gag release (supernatant p24/(supernatant + cellular p55/p24)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. (D) Quantitative analysis of the effect of depleting the individual genes on M-PMV particle release. M-PMV particle release in the control shRNA or specific shRNA expressing Cos-1 cells was assessed by immunoblotting with p27 antibody. The supernatant p27 and cellular p27 and Pr78 Gag were quantified on the LiCor Odyssey. Results were expressed as percentage Gag release (supernatant p27/(supernatant + cellular Pr78 Gag /p27)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments.

    Journal: PLoS ONE

    Article Title: An siRNA Screen of Membrane Trafficking Genes Highlights Pathways Common to HIV-1 and M-PMV Virus Assembly and Release

    doi: 10.1371/journal.pone.0106151

    Figure Lengend Snippet: Effect of silencing of TSG101, ALIX1, AP1M1, BECN1 and SARA1 on HIV-1 and M-PMV particle output. (A) Quantitative western blots showing knockdown efficiency of the individual genes in Jurkat cells and Cos-1 cells. Jurkat cells and Cos-1 cells stably expressing control shRNA or specific shRNAs against individual genes were generated, and the cellular levels of the individual proteins examined by immunoblotting. The ratio of the individual protein levels as quantified on the LiCor Odyssey compared to control cell is shown below each blot. (B) The effect of depleting the individual genes on M-PMV particle output. Cos-1 cells stably expressing control shRNA or the indicated shRNAs were transfected with pSARMX M-PMV proviral vector. At 48 hours after transfection, the virions in the supernatant and cell lysates were harvested and subjected to immunoblotting with p27 antibody. The ratio of supernatant p27 and the ratio of the total amount of cellular p27 and Pr78 Gag as quantified on the LiCor Odyssey compared to control cells are shown below each blot. (C) The effect of depleting the individual genes on HIV-1 particle release in Jurkat cells. Control shRNA or specific shRNA expressing Jurkat cells were infected with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-NL4-3 virus (at 1 TCID 50 ) overnight at 37°C, washed and then seeded in 12-well plates. HIV-1 particle release was assessed using a p24 antigen ELISA 2 days post-infection. Results were expressed as percentage Gag release (supernatant p24/(supernatant + cellular p55/p24)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments. (D) Quantitative analysis of the effect of depleting the individual genes on M-PMV particle release. M-PMV particle release in the control shRNA or specific shRNA expressing Cos-1 cells was assessed by immunoblotting with p27 antibody. The supernatant p27 and cellular p27 and Pr78 Gag were quantified on the LiCor Odyssey. Results were expressed as percentage Gag release (supernatant p27/(supernatant + cellular Pr78 Gag /p27)) normalized to control shRNA-expressing cells. Error bars indicate the standard deviation of three independent experiments.

    Article Snippet: We identified 24 host proteins involved in intracellular trafficking that affected both HIV-1 and M-PMV assembly and release.

    Techniques: Western Blot, Stable Transfection, Expressing, shRNA, Generated, Transfection, Plasmid Preparation, Infection, Enzyme-linked Immunosorbent Assay, Standard Deviation

    Effect of silencing the selected genes on HIV1 particle output. (A) Quantitative western blot analysis of knockdown efficiency of the individual genes in HeLa cells. HeLa cells stably expressing control shRNA or specific shRNAs against each individual gene were generated and the cellular levels of the individual protein were examined. The ratio of the individual protein levels as quantified on the LiCor Odyssey compared to control cell is shown below each blot. (B) The effect of depleting the individual genes on HIV-1 particle output. HeLa cells stably expressing control shRNA or the indicated shRNAs were transfected with NL4-3 HIV proviral vector. At 48 hours after transfection, the virions in the supernatant and cell lysates were harvested and subjected to immunoblotting with p24 antibody. The ratio of supernatant p24 and the ratio of the total amount of cellular p24 and p55 as quantified on the LiCor Odyssey compared to control cells are shown below each blot.

    Journal: PLoS ONE

    Article Title: An siRNA Screen of Membrane Trafficking Genes Highlights Pathways Common to HIV-1 and M-PMV Virus Assembly and Release

    doi: 10.1371/journal.pone.0106151

    Figure Lengend Snippet: Effect of silencing the selected genes on HIV1 particle output. (A) Quantitative western blot analysis of knockdown efficiency of the individual genes in HeLa cells. HeLa cells stably expressing control shRNA or specific shRNAs against each individual gene were generated and the cellular levels of the individual protein were examined. The ratio of the individual protein levels as quantified on the LiCor Odyssey compared to control cell is shown below each blot. (B) The effect of depleting the individual genes on HIV-1 particle output. HeLa cells stably expressing control shRNA or the indicated shRNAs were transfected with NL4-3 HIV proviral vector. At 48 hours after transfection, the virions in the supernatant and cell lysates were harvested and subjected to immunoblotting with p24 antibody. The ratio of supernatant p24 and the ratio of the total amount of cellular p24 and p55 as quantified on the LiCor Odyssey compared to control cells are shown below each blot.

    Article Snippet: We identified 24 host proteins involved in intracellular trafficking that affected both HIV-1 and M-PMV assembly and release.

    Techniques: Western Blot, Stable Transfection, Expressing, shRNA, Generated, Transfection, Plasmid Preparation

    Endpoint Algorithm for Diagnosis of HIV-1 Infection used at Clinical Sites during the VOICE Study. Participants were monitored monthly for seroconversion with one (Uganda) or two (South Africa and Zimbabwe) third generation HIV rapid diagnostic tests including Alere Determine™ HIV-1/2, OraQuick ADVANCE ® Rapid HIV-1/2 Antibody Test and/or Uni-Gold™ Recombigen ® HIV-1/2. Positive or discordant results were confirmed by GS HIV-1 Western Blot (Western Blot 1) using plasma from a separate draw. HIV-1 RNA PCR (HIV viral load) was performed on plasma following an indeterminate or negative Western blot result to assess acute infection. Participants confirmed as HIV-uninfected resumed study product and continued in VOICE while participants whose Western Blot tested positive returned to the study site to have a second Western blot performed on plasma from a separate draw. A second positive Western blot confirmed HIV infection and the participant was exited from the study. Discordant results underwent investigation and further testing by the Study Laboratory Management Group.

    Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

    Article Title: The fourth generation Alere™ HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples

    doi: 10.1016/j.jcv.2017.06.006

    Figure Lengend Snippet: Endpoint Algorithm for Diagnosis of HIV-1 Infection used at Clinical Sites during the VOICE Study. Participants were monitored monthly for seroconversion with one (Uganda) or two (South Africa and Zimbabwe) third generation HIV rapid diagnostic tests including Alere Determine™ HIV-1/2, OraQuick ADVANCE ® Rapid HIV-1/2 Antibody Test and/or Uni-Gold™ Recombigen ® HIV-1/2. Positive or discordant results were confirmed by GS HIV-1 Western Blot (Western Blot 1) using plasma from a separate draw. HIV-1 RNA PCR (HIV viral load) was performed on plasma following an indeterminate or negative Western blot result to assess acute infection. Participants confirmed as HIV-uninfected resumed study product and continued in VOICE while participants whose Western Blot tested positive returned to the study site to have a second Western blot performed on plasma from a separate draw. A second positive Western blot confirmed HIV infection and the participant was exited from the study. Discordant results underwent investigation and further testing by the Study Laboratory Management Group.

    Article Snippet: RDTs used included Alere Determine™ HIV-1/2 (Alere Medical Co. Ltd., Matsudo, Japan), OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test (OraSure Technologies, Inc., Bethlehem, PA) and/or Uni-Gold™ Recombigen® HIV-1/2 rapid test (Trinity Biotech™ Wicklow, Ireland).

    Techniques: Infection, Diagnostic Assay, Western Blot, Polymerase Chain Reaction

    Treatment of NFκ-B inhibitors reduce HIV-1 replication in U1 cells due to BaP exposure. U1 cells were concomitantly treated with BaP (1 µM) and NFκ-B inhibitors, IKK-16 (400 nM) ( A ), and SC-514 (10 µM) ( B ) for 3 days. After the treatment, supernatants were collected to determine the viral load using the p24 ELISA assay. HIV-1 replication due to BaP (1 µM) exposure was significantly rescued by NFκ-B inhibitors, IKK-16 (400 nM) and SC-514 (10 µM). *Represents p ≤ 0.05 compared with the control group while ## represents p ≤ 0.005 compared to the BaP-treated groups. Western blots were run using the nuclear fraction proteins obtained from the BaP-exposed cells treated with IKK-16 ( C ) SC-524 ( D ) or siRNA CYP1A1 ( E ) to determine the expression of NFκ-B p65 subunits. The blots indicate that treatment with both the NFκ-B inhibitors and CYP1A1 siRNA reduced the expression of NFκ-B p65 in the nuclear fraction protein of the BaP-treated cells compared to the control. The blots presented are representative of at least three different experiments.

    Journal: Scientific Reports

    Article Title: Benzo(a)pyrene in Cigarette Smoke Enhances HIV-1 Replication through NF-κB Activation via CYP-Mediated Oxidative Stress Pathway

    doi: 10.1038/s41598-018-28500-z

    Figure Lengend Snippet: Treatment of NFκ-B inhibitors reduce HIV-1 replication in U1 cells due to BaP exposure. U1 cells were concomitantly treated with BaP (1 µM) and NFκ-B inhibitors, IKK-16 (400 nM) ( A ), and SC-514 (10 µM) ( B ) for 3 days. After the treatment, supernatants were collected to determine the viral load using the p24 ELISA assay. HIV-1 replication due to BaP (1 µM) exposure was significantly rescued by NFκ-B inhibitors, IKK-16 (400 nM) and SC-514 (10 µM). *Represents p ≤ 0.05 compared with the control group while ## represents p ≤ 0.005 compared to the BaP-treated groups. Western blots were run using the nuclear fraction proteins obtained from the BaP-exposed cells treated with IKK-16 ( C ) SC-524 ( D ) or siRNA CYP1A1 ( E ) to determine the expression of NFκ-B p65 subunits. The blots indicate that treatment with both the NFκ-B inhibitors and CYP1A1 siRNA reduced the expression of NFκ-B p65 in the nuclear fraction protein of the BaP-treated cells compared to the control. The blots presented are representative of at least three different experiments.

    Article Snippet: We used the HIV-1 p24 Antigen ELISA kit (Zeptometrix Corporation, Buffalo, NY) for this purpose.

    Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Expressing

    Treatment of antioxidants and CYP1A1 inhibitors reduce HIV-1 replication in U1 cells due to BaP exposure. U1 cells were concomitantly treated with BaP (1 µM) and antioxidants [vitamin C (100 µM) and vitamin E (100 µM), pinostilbene (2 µM), and resveratrol (50 µM)] ( A ) or CYP1A1 inhibitor ellipticine (1 µM)] ( B ) for 3 days. Prior to BaP treatment, the CYP1A1 gene was knocked down in the U1 cells using siRNA specific to CYP1A1. ( C ) The cells were then treated with BaP (100 nM) for 3 days. After the treatment, supernatants were collected to determine the viral load using the p24 ELISA assay. HIV-1 replication significantly increased with 3-days exposure of BaP (1 µM), which was rescued by all the antioxidants (vitamin C and E, and resveratrol) as well as the CYP1A1 inhibitor, ellipticine . The knock-down of the CYP1A1 gene also rescued HIV-1 replication in BaP-exposed U1 cells. The data were obtained from the mean of at least three independent experiments. * and ** represents p ≤ 0.05 and p ≤ 0.005 compared with the control group while #,## and ### represents p ≤ 0.05, p ≤ 0.005 and p ≤ 0.0005, respectively, compared to the BaP-treated groups.

    Journal: Scientific Reports

    Article Title: Benzo(a)pyrene in Cigarette Smoke Enhances HIV-1 Replication through NF-κB Activation via CYP-Mediated Oxidative Stress Pathway

    doi: 10.1038/s41598-018-28500-z

    Figure Lengend Snippet: Treatment of antioxidants and CYP1A1 inhibitors reduce HIV-1 replication in U1 cells due to BaP exposure. U1 cells were concomitantly treated with BaP (1 µM) and antioxidants [vitamin C (100 µM) and vitamin E (100 µM), pinostilbene (2 µM), and resveratrol (50 µM)] ( A ) or CYP1A1 inhibitor ellipticine (1 µM)] ( B ) for 3 days. Prior to BaP treatment, the CYP1A1 gene was knocked down in the U1 cells using siRNA specific to CYP1A1. ( C ) The cells were then treated with BaP (100 nM) for 3 days. After the treatment, supernatants were collected to determine the viral load using the p24 ELISA assay. HIV-1 replication significantly increased with 3-days exposure of BaP (1 µM), which was rescued by all the antioxidants (vitamin C and E, and resveratrol) as well as the CYP1A1 inhibitor, ellipticine . The knock-down of the CYP1A1 gene also rescued HIV-1 replication in BaP-exposed U1 cells. The data were obtained from the mean of at least three independent experiments. * and ** represents p ≤ 0.05 and p ≤ 0.005 compared with the control group while #,## and ### represents p ≤ 0.05, p ≤ 0.005 and p ≤ 0.0005, respectively, compared to the BaP-treated groups.

    Article Snippet: We used the HIV-1 p24 Antigen ELISA kit (Zeptometrix Corporation, Buffalo, NY) for this purpose.

    Techniques: Enzyme-linked Immunosorbent Assay

    Chronic treatment of BaP induces HIV-1 replication and apoptotic DNA damage in HIV-1-infected macrophages. ( A ) The U1 cells were treated with 10 nM and 100 nM BaP for seven days. After the BaP treatment, the U1 cells were stimulated with 100 nM of Phorbol 12-myristate 13-acetate (PMA) to produce HIV-1. Supernatants were collected after two days of differentiation, which were used for the p24 ELISA assay to assess the viral load. The chronic (7 days) treatment of BaP (100 nM) significantly increased the viral replication in U1 cells, while the 10-fold lower concentration did not have any significant effect. The data is displayed as mean ± SEM (n = 6), calculated as a percentage of the control. ( B ) HIV-infected human primary macrophages were treated with BaP (100 nM) for 3 days. The supernatant was collected thereafter and used for the p24 ELISA assay to assess the viral load. The acute (3 days) treatment of BaP (100 nM) significantly increased the viral replication in HIV-1-infected primary macrophages. The data is displayed as mean ± SEM (n = 4). For calculating the viral load, we subtracted the nonspecific background reading from the actual absorbance values. Since the residual viral load varies from experiment to experiment in U1 cells, we normalized the control values for each experiment to 100% and calculated the values for the treated, as the percentage of the control. The statistical significance was calculated at *p ≤ 0.05, where *** represents p ≤ 0.0005, compared with the control group. ( C ) The apoptotic DNA damage assay was performed on the treated cells. DAPI, FAM and CR590 stained nucleus (blue), apoptotic DNA damage with DNase Type II ends (green) and Type I ends (red) respectively. A higher signal for CR590 is visible in the fluorescent images, indicating apoptotic DNA fragmentation with DNase Type I ends in the infected human primary macrophages after BaP (100 nM) exposure for 3 days. DNA fragmentation with DNase Type II ends (green) was not visible in either the control or the treated cells. Therefore, the images indicate that BaP (100 nM) induces DNA fragmentation during the early phase of apoptosis in the HIV-1-infected human primary macrophages.

    Journal: Scientific Reports

    Article Title: Benzo(a)pyrene in Cigarette Smoke Enhances HIV-1 Replication through NF-κB Activation via CYP-Mediated Oxidative Stress Pathway

    doi: 10.1038/s41598-018-28500-z

    Figure Lengend Snippet: Chronic treatment of BaP induces HIV-1 replication and apoptotic DNA damage in HIV-1-infected macrophages. ( A ) The U1 cells were treated with 10 nM and 100 nM BaP for seven days. After the BaP treatment, the U1 cells were stimulated with 100 nM of Phorbol 12-myristate 13-acetate (PMA) to produce HIV-1. Supernatants were collected after two days of differentiation, which were used for the p24 ELISA assay to assess the viral load. The chronic (7 days) treatment of BaP (100 nM) significantly increased the viral replication in U1 cells, while the 10-fold lower concentration did not have any significant effect. The data is displayed as mean ± SEM (n = 6), calculated as a percentage of the control. ( B ) HIV-infected human primary macrophages were treated with BaP (100 nM) for 3 days. The supernatant was collected thereafter and used for the p24 ELISA assay to assess the viral load. The acute (3 days) treatment of BaP (100 nM) significantly increased the viral replication in HIV-1-infected primary macrophages. The data is displayed as mean ± SEM (n = 4). For calculating the viral load, we subtracted the nonspecific background reading from the actual absorbance values. Since the residual viral load varies from experiment to experiment in U1 cells, we normalized the control values for each experiment to 100% and calculated the values for the treated, as the percentage of the control. The statistical significance was calculated at *p ≤ 0.05, where *** represents p ≤ 0.0005, compared with the control group. ( C ) The apoptotic DNA damage assay was performed on the treated cells. DAPI, FAM and CR590 stained nucleus (blue), apoptotic DNA damage with DNase Type II ends (green) and Type I ends (red) respectively. A higher signal for CR590 is visible in the fluorescent images, indicating apoptotic DNA fragmentation with DNase Type I ends in the infected human primary macrophages after BaP (100 nM) exposure for 3 days. DNA fragmentation with DNase Type II ends (green) was not visible in either the control or the treated cells. Therefore, the images indicate that BaP (100 nM) induces DNA fragmentation during the early phase of apoptosis in the HIV-1-infected human primary macrophages.

    Article Snippet: We used the HIV-1 p24 Antigen ELISA kit (Zeptometrix Corporation, Buffalo, NY) for this purpose.

    Techniques: Infection, Enzyme-linked Immunosorbent Assay, Concentration Assay, Staining

    3.1. Sensitivity and specificity of RDTs in the detection of HIV

    Journal: Journal of Clinical Laboratory Analysis

    Article Title: Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon), et al. Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon)

    doi: 10.1002/jcla.22824

    Figure Lengend Snippet: 3.1. Sensitivity and specificity of RDTs in the detection of HIV

    Article Snippet: We assessed the sensitivity of RDTs for HIV (Alere DETERMINE, BIOSYNEX Exacto® Pro HIV, and MEDIFF HIV 1 & 2 Serum/sang Total Cassette) and HBV detection (BIOSYNEX IMMUNOQUICK® HBsAg) in Libreville blood donors.

    Techniques:

    3.1. Sensitivity and specificity of RDTs in the detection of HIV

    Journal: Journal of Clinical Laboratory Analysis

    Article Title: Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon), et al. Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon)

    doi: 10.1002/jcla.22824

    Figure Lengend Snippet: 3.1. Sensitivity and specificity of RDTs in the detection of HIV

    Article Snippet: We assessed the sensitivity of RDTs for HIV (Alere DETERMINE, BIOSYNEX Exacto® Pro HIV, and MEDIFF HIV 1 & 2 Serum/sang Total Cassette) and HBV detection (BIOSYNEX IMMUNOQUICK® HBsAg) in Libreville blood donors.

    Techniques:

    3.2. Comparison of Alere DETERMINE and BIOSYNEX Exacto® Pro HIV or MEDIFF HIV 1 & 2 Serum/sang Total Cassette for the detection of HIV

    Journal: Journal of Clinical Laboratory Analysis

    Article Title: Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon), et al. Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon)

    doi: 10.1002/jcla.22824

    Figure Lengend Snippet: 3.2. Comparison of Alere DETERMINE and BIOSYNEX Exacto® Pro HIV or MEDIFF HIV 1 & 2 Serum/sang Total Cassette for the detection of HIV

    Article Snippet: We assessed the sensitivity of RDTs for HIV (Alere DETERMINE, BIOSYNEX Exacto® Pro HIV, and MEDIFF HIV 1 & 2 Serum/sang Total Cassette) and HBV detection (BIOSYNEX IMMUNOQUICK® HBsAg) in Libreville blood donors.

    Techniques:

    3.1. Sensitivity and specificity of RDTs in the detection of HIV

    Journal: Journal of Clinical Laboratory Analysis

    Article Title: Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon), et al. Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon)

    doi: 10.1002/jcla.22824

    Figure Lengend Snippet: 3.1. Sensitivity and specificity of RDTs in the detection of HIV

    Article Snippet: We assessed the sensitivity of RDTs for HIV (Alere DETERMINE, BIOSYNEX Exacto® Pro HIV, and MEDIFF HIV 1 & 2 Serum/sang Total Cassette) and HBV detection (BIOSYNEX IMMUNOQUICK® HBsAg) in Libreville blood donors.

    Techniques:

    Prevalence of HIV-1 and HIV-2 in pregnant women by calendar year, Simão Mendes National Hospital, Bissau, Guinea-Bissau, 2008–2013. The figure displays the changes in HIV-1 ( a ), HIV-2 ( b ), and HIV-1/2 ( c ) prevalence (point estimates and corresponding 95% confidence intervals) among pregnant women presenting for birth by calendar year. HIV-1, HIV-2 and HIV-1/2 all declined significantly from 2009 to 2013 (chi 2 test for trend).

    Journal: Scientific Reports

    Article Title: HIV-1 and HIV-2 prevalence, risk factors and birth outcomes among pregnant women in Bissau, Guinea-Bissau: a retrospective cross-sectional hospital study

    doi: 10.1038/s41598-020-68806-5

    Figure Lengend Snippet: Prevalence of HIV-1 and HIV-2 in pregnant women by calendar year, Simão Mendes National Hospital, Bissau, Guinea-Bissau, 2008–2013. The figure displays the changes in HIV-1 ( a ), HIV-2 ( b ), and HIV-1/2 ( c ) prevalence (point estimates and corresponding 95% confidence intervals) among pregnant women presenting for birth by calendar year. HIV-1, HIV-2 and HIV-1/2 all declined significantly from 2009 to 2013 (chi 2 test for trend).

    Article Snippet: HIV type discrimination was performed using SD Bioline HIV-1/2 3.0.

    Techniques:

    Ex vivo HIV-specific CD4+ and CD8+ T cells induced by the Merck trivalent Ad5/HIV vaccine. A) Cytokine and activation marker flow cytometric staining profiles in previously cryopreserved PBMC from one vaccine recipient obtained four weeks after the third immunization (week 30). The Ad5 neutralizing titer for this individual is 893. Cells were gated by forward and side scatter, live vs. dead cells, CD3+ T cells, and then CD4+ and CD8+ T cells. HIV-specific CD4+ (left two columns) and CD8+ (right two columns) T cells were stimulated ex vivo with Gag, Pol and Nef peptide pools that span the sequence encoded by the HIV-1 gene insert. The numbers indicate the percent of CD4+ or CD8+ cells expressing cytokine(s) IFN-γ, IL-2 and/or TNF-α. The responses in the negative control were low (

    Journal: Lancet

    Article Title: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

    doi: 10.1016/S0140-6736(08)61592-5

    Figure Lengend Snippet: Ex vivo HIV-specific CD4+ and CD8+ T cells induced by the Merck trivalent Ad5/HIV vaccine. A) Cytokine and activation marker flow cytometric staining profiles in previously cryopreserved PBMC from one vaccine recipient obtained four weeks after the third immunization (week 30). The Ad5 neutralizing titer for this individual is 893. Cells were gated by forward and side scatter, live vs. dead cells, CD3+ T cells, and then CD4+ and CD8+ T cells. HIV-specific CD4+ (left two columns) and CD8+ (right two columns) T cells were stimulated ex vivo with Gag, Pol and Nef peptide pools that span the sequence encoded by the HIV-1 gene insert. The numbers indicate the percent of CD4+ or CD8+ cells expressing cytokine(s) IFN-γ, IL-2 and/or TNF-α. The responses in the negative control were low (

    Article Snippet: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

    Techniques: Ex Vivo, Activation Assay, Marker, Flow Cytometry, Staining, Sequencing, Expressing, Negative Control

    Structural models of (A) BI-1001, (B) CX14442 in complex with HIV-1 IN CCD dimer. The averaged structures extracted from the MD trajectories were used. The proteins are shown in cartoon representation with two monomers in yellow and cyan. The BI-1001 and CX14442 are shown in gray stick model. Hydrogen bond interactions are denoted by dotted green or blue lines.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: Structural models of (A) BI-1001, (B) CX14442 in complex with HIV-1 IN CCD dimer. The averaged structures extracted from the MD trajectories were used. The proteins are shown in cartoon representation with two monomers in yellow and cyan. The BI-1001 and CX14442 are shown in gray stick model. Hydrogen bond interactions are denoted by dotted green or blue lines.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques:

    Structural model of LEDGF/p75 in complex with HIV-1 IN CCD dimer. The averaged structure extracted from the MD trajectory was used. The protein is shown in cartoon representation with two monomers in yellow and cyan. The side chains of the LEDGF/p75 amino acids are shown as gray sticks. Hydrogen bond interactions are denoted by dotted green lines.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: Structural model of LEDGF/p75 in complex with HIV-1 IN CCD dimer. The averaged structure extracted from the MD trajectory was used. The protein is shown in cartoon representation with two monomers in yellow and cyan. The side chains of the LEDGF/p75 amino acids are shown as gray sticks. Hydrogen bond interactions are denoted by dotted green lines.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques:

    Per-residue interaction spectrum of the residues of HIV-1 IN CCD with (A) BI-1001, (B) CX14442, and (C) LEDGF/p75 in complex with the HIV-1 IN CCD dimer from MM/GBSA free energy decomposition analysis.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: Per-residue interaction spectrum of the residues of HIV-1 IN CCD with (A) BI-1001, (B) CX14442, and (C) LEDGF/p75 in complex with the HIV-1 IN CCD dimer from MM/GBSA free energy decomposition analysis.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques:

    Scheme of the active site DDE motif (Asp64, Asp116, and Glu152) models for (A) LEDGF/p75, (B) BI-1001 and (C) CX14442 bound HIV-1 IN complexes. The measured distances between the centroid of the side chains of the three conserved catalytic residues were labeled in each model.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: Scheme of the active site DDE motif (Asp64, Asp116, and Glu152) models for (A) LEDGF/p75, (B) BI-1001 and (C) CX14442 bound HIV-1 IN complexes. The measured distances between the centroid of the side chains of the three conserved catalytic residues were labeled in each model.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques: Labeling

    The generated pharmacophore for HIV-1 IN LEDGINs based on the receptor-ligand interactions. The model consists of hydrophobic and hydrophilic features on LEDGINs as well as the key residue in HIV-1 IN allosteric site. The hydrophobic and hydrophilic domains are shown in green and red, respectively. The residues that participated in the interaction between LEDGINs and HIV-1 IN CCD are labeled in cyan and orange, while the potential residues used for further extension LEDGINs design are labeled in black and gray.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: The generated pharmacophore for HIV-1 IN LEDGINs based on the receptor-ligand interactions. The model consists of hydrophobic and hydrophilic features on LEDGINs as well as the key residue in HIV-1 IN allosteric site. The hydrophobic and hydrophilic domains are shown in green and red, respectively. The residues that participated in the interaction between LEDGINs and HIV-1 IN CCD are labeled in cyan and orange, while the potential residues used for further extension LEDGINs design are labeled in black and gray.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques: Generated, Labeling

    The LEDGF/p75 protein residues contribution to the total binding free energy of the LEDGF/p75 bound HIV-1 IN CCD complex.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: The LEDGF/p75 protein residues contribution to the total binding free energy of the LEDGF/p75 bound HIV-1 IN CCD complex.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques: Binding Assay

    Structure of LEDGINs and HIV-1 IN CCD dimer. (A) Chemical structures of BI-1001 and CX14442. (B) Crystal structure of BI-1001 bound to the HIV-1 IN CCD dimer interface (PDB ID code 4DMN). The monomers are distinguished in yellow and cyan, and the BI-1001 is shown in gray stick model. The constructed missing loop (residues 141 to 151) is colored gray. The allosteric site at the HIV-1 IN CCD dimer interface is represented by surface. HIV-1 IN active site residues (Asp64, Asp116, and Glu152) are shown in cyan stick.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: Structure of LEDGINs and HIV-1 IN CCD dimer. (A) Chemical structures of BI-1001 and CX14442. (B) Crystal structure of BI-1001 bound to the HIV-1 IN CCD dimer interface (PDB ID code 4DMN). The monomers are distinguished in yellow and cyan, and the BI-1001 is shown in gray stick model. The constructed missing loop (residues 141 to 151) is colored gray. The allosteric site at the HIV-1 IN CCD dimer interface is represented by surface. HIV-1 IN active site residues (Asp64, Asp116, and Glu152) are shown in cyan stick.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques: Construct

    The monitored RMSD of the backbone atoms of protein (black), backbone atoms of binding pocket residues around 5 Å of ligand (blue), and the heavy atoms in the ligand (red) for: (A) BI-1001 and (B) CX14442 bound HIV-1 IN complexes with respect to the initial structures as a function of time. (C) The monitored RMSD of the backbone atoms of HIV-1 IN and LEDGF/p75 (black), backbone atoms of HIV-1 IN (blue), and backbone atoms of LEDGF/p75 (red) for LEDGF/p75 bound HIV-1 IN complex with respect to the initial structures as a function of time.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: The monitored RMSD of the backbone atoms of protein (black), backbone atoms of binding pocket residues around 5 Å of ligand (blue), and the heavy atoms in the ligand (red) for: (A) BI-1001 and (B) CX14442 bound HIV-1 IN complexes with respect to the initial structures as a function of time. (C) The monitored RMSD of the backbone atoms of HIV-1 IN and LEDGF/p75 (black), backbone atoms of HIV-1 IN (blue), and backbone atoms of LEDGF/p75 (red) for LEDGF/p75 bound HIV-1 IN complex with respect to the initial structures as a function of time.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques: Binding Assay

    The aligned representative conformations of BI-1001, CX14442, and LEDGF/p75 bound HIV-1 IN CCD dimer models. The averaged structures extracted from the MD trajectories were used. The BI-1001, CX14442, and LEDGF/p75 bound form are shown in yellow, cyan and gray, respectively. HIV-1 IN active site residues (Asp64, Asp116, and Glu152) are shown in stick. The LEDGINs and LEDGF/p75 are represented in stick and carton, respectively.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: The aligned representative conformations of BI-1001, CX14442, and LEDGF/p75 bound HIV-1 IN CCD dimer models. The averaged structures extracted from the MD trajectories were used. The BI-1001, CX14442, and LEDGF/p75 bound form are shown in yellow, cyan and gray, respectively. HIV-1 IN active site residues (Asp64, Asp116, and Glu152) are shown in stick. The LEDGINs and LEDGF/p75 are represented in stick and carton, respectively.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques:

    Comparison of the computational docking of CX14442 in the HIV-1 IN CCD dimer versus the reported crystal structure of BI-1001 bound in HIV-1 IN CCD dimer (PDB ID code 4DMN). The protein is shown in the cartoon representation; the two monomers are colored yellow and cyan, respectively. The LEDGINs are represented in gray stick. Hydrogen bond interactions are denoted by dotted green lines.

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: Comparison of the computational docking of CX14442 in the HIV-1 IN CCD dimer versus the reported crystal structure of BI-1001 bound in HIV-1 IN CCD dimer (PDB ID code 4DMN). The protein is shown in the cartoon representation; the two monomers are colored yellow and cyan, respectively. The LEDGINs are represented in gray stick. Hydrogen bond interactions are denoted by dotted green lines.

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques:

    Electrostatic potential surface of the allosteric binding pocket of HIV-1 IN CCD dimer in interaction with (A) BI-1001, (B) CX14442, and (C) LEDGF/p75. The positive charges are displayed in blue, negative charges are displayed in red, and neutral residues are displayed in white. Color intensity is proportional to the charge value. The BI-1001, CX14442 and side chain of the LEDGF/p75 key residues, whose carbon atoms are shown as green spheres and labeled as red. The residue Trp131 from monomer A of HIV-1 CCD dimer is also labeled (black).

    Journal: PLoS ONE

    Article Title: Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

    doi: 10.1371/journal.pone.0090799

    Figure Lengend Snippet: Electrostatic potential surface of the allosteric binding pocket of HIV-1 IN CCD dimer in interaction with (A) BI-1001, (B) CX14442, and (C) LEDGF/p75. The positive charges are displayed in blue, negative charges are displayed in red, and neutral residues are displayed in white. Color intensity is proportional to the charge value. The BI-1001, CX14442 and side chain of the LEDGF/p75 key residues, whose carbon atoms are shown as green spheres and labeled as red. The residue Trp131 from monomer A of HIV-1 CCD dimer is also labeled (black).

    Article Snippet: Supporting Information Structural models of BI-1001 and LEDGF/p75-bound HIV-1 IN CCD dimer complexes. (A) The modified crystal structures of BI-1001 in complex with HIV-1 IN CCD (PDB ID code 4DMN). (B) The crystal structures of LEDGF/p75 in complex with HIV-1 IN CCD (PDB ID code 2B4J).

    Techniques: Binding Assay, Labeling

    Application of the broadly sensitive genotyping assay in the surveillance of transmitted HIV-1 drug resistance in resource-limited countries.

    Journal: Journal of Clinical Microbiology

    Article Title: Development and Application of a Broadly Sensitive Dried-Blood-Spot-Based Genotyping Assay for Global Surveillance of HIV-1 Drug Resistance ▿

    doi: 10.1128/JCM.00564-10

    Figure Lengend Snippet: Application of the broadly sensitive genotyping assay in the surveillance of transmitted HIV-1 drug resistance in resource-limited countries.

    Article Snippet: However, the current 5′ nested-PCR primer (Prt-F2) for the protease region starting at codon 13 is a few amino acids shorter than those in commonly used genotyping assays, such as the Trugene HIV-1 genotyping system (Siemans Medical Solutions Diagnostics, Tarrytown, NY) and the Viroseq HIV-1 genotyping system (Celera Diagnostics, Alameda, CA), and does not cover all the amino acid positions associated with DR against protease inhibitors.

    Techniques: Genotyping Assay

    HIV-specific antibodies Humoral response dynamics were tested up to 1316 days after allo-HSCT. Antibody levels were measured using the standard HIV-1 Vitros assay (A), a detuned low-sensitive version of the HIV-1 Vitros assay (B), and the limiting antigen avidity assay (C). White circles represent values under the LOD. Grey shading denotes the period off cART. Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. cART=combined antiretroviral therapy. LOD=limit of detection.

    Journal: The Lancet. HIV

    Article Title: Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

    doi: 10.1016/S2352-3018(20)30069-2

    Figure Lengend Snippet: HIV-specific antibodies Humoral response dynamics were tested up to 1316 days after allo-HSCT. Antibody levels were measured using the standard HIV-1 Vitros assay (A), a detuned low-sensitive version of the HIV-1 Vitros assay (B), and the limiting antigen avidity assay (C). White circles represent values under the LOD. Grey shading denotes the period off cART. Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. cART=combined antiretroviral therapy. LOD=limit of detection.

    Article Snippet: We then tested the suspension using the Hologic Aptima HIV-1 Quant Dx assay (Marlborough, MA, USA).

    Techniques: Transplantation Assay

    Clinical course of the London patient up to 29 months after analytical treatment interruption Upper panel shows peripheral blood CD4 count, plasma HIV-1 RNA, HIV-1 DNA, and chimerism in peripheral T cells over time. Lower panel shows amounts in DNA of CMV and EBV in plasma over time. Anti-CD52 was alemtuzumab. 3TC=lamivudine. Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. cART=combination antiretroviral therapy. CMV=cytomegalovirus. CsA=ciclosporin. DTG=dolutegravir. EBV=Epstein-Barr virus. GvHD=graft versus host disease. FTC=emtricitabine. LACE=lomustine, cytarabine, cyclophosphamide, and etoposide. MTX=methotrexate. RAL=raltegravir. RPV=rilpivirine. TDF=tenofovir disoproxil fumarate.

    Journal: The Lancet. HIV

    Article Title: Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

    doi: 10.1016/S2352-3018(20)30069-2

    Figure Lengend Snippet: Clinical course of the London patient up to 29 months after analytical treatment interruption Upper panel shows peripheral blood CD4 count, plasma HIV-1 RNA, HIV-1 DNA, and chimerism in peripheral T cells over time. Lower panel shows amounts in DNA of CMV and EBV in plasma over time. Anti-CD52 was alemtuzumab. 3TC=lamivudine. Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. cART=combination antiretroviral therapy. CMV=cytomegalovirus. CsA=ciclosporin. DTG=dolutegravir. EBV=Epstein-Barr virus. GvHD=graft versus host disease. FTC=emtricitabine. LACE=lomustine, cytarabine, cyclophosphamide, and etoposide. MTX=methotrexate. RAL=raltegravir. RPV=rilpivirine. TDF=tenofovir disoproxil fumarate.

    Article Snippet: We then tested the suspension using the Hologic Aptima HIV-1 Quant Dx assay (Marlborough, MA, USA).

    Techniques: Transplantation Assay